Catapres-TTS-3 Transdermal and Cotempla XR-ODT

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Before using cloNIDine, tell your doctor if you also use methylphenidate. Taking these drugs together can affect the rhythm of your heart. Call your doctor if you have symptoms of irregular heartbeat, chest tightness, blurred vision or nausea. You may need a dose adjustment or need your blood pressure checked more often if you take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Serious adverse events may occur during concomitant use of methylphenidate or dexmethylphenidate with centrally-acting alpha-2 agonists. The mechanism of interaction, if any, is unknown, and a causal relationship has not been established. The use of clonidine, with or without methylphenidate, has been associated with rare cases of sudden death and cardiotoxicity including sinus bradycardia and heart block. Electrocardiographic (ECG) abnormalities have also been demonstrated in patients treated with clonidine, even at low dosages. However, some investigators suggest these findings may reflect the pharmacologic effects of the drug and not necessarily cardiotoxic effects. Although the existence of a methylphenidate-clonidine interaction is questionable, it is possible that the combination may be more dangerous than either drug alone with respect to drug discontinuation. Specifically, methylphenidate may exacerbate the rebound hypertension and hyperadrenergic state associated with abrupt withdrawal of clonidine, and methylphenidate withdrawal may aggravate the bradycardia and hypotension associated with clonidine use.

MANAGEMENT: The safety of using methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) in combination with clonidine or other centrally-acting alpha-2 agonists has not been established. Patients being considered for alpha-2 agonist therapy, alone or with methylphenidate or dexmethylphenidate, should have cardiovascular status and history evaluated. Vital signs, including pulse and blood pressure, should be monitored prior to and during therapy. The routine use of ECGs in patients being treated for behavioral disorders is controversial, since it is uncertain what findings may indicate actual risk for sudden death. However, ECG monitoring may be appropriate in cases of preexisting cardiac disease or abnormal finding on physical examination. Finally, patients should be advised not to abruptly discontinue the alpha-2 agonist, methylphenidate, or dexmethylphenidate following chronic use unless otherwise directed by their physician.

Catapres-TTS-3 Transdermal

Generic Name: clonidine

Brand name: Catapres-TTS-1, Catapres-TTS-2, Catapres-TTS-3, Catapres, Catapres-TTS, Duraclon, Kapvay

Synonyms: Catapres-TTS

What is Catapres-TTS-3 Transdermal?

Cotempla XR-ODT

Generic Name: methylphenidate

Brand name: Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT, Jornay PM, Metadate ER, Methylin, QuilliChew ER, Quillivant XR, Relexxii, Ritalin, Ritalin LA, Metadate CD, Ritalin SR, Daytrana, Methylin ER

Synonyms: n.a.

What is Cotempla XR-ODT?